An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Males and Females, age ≥ 18 years old * Newly diagnosed brain cancer or tumor called glioblastoma or GBM * Karnofsky performance status of ≥ 70 (able to take care of self) * Substantial recovery from surgery resection * Tumor test result shows MGMT methylated or indeterminate tumor subtype Exclusion Criteria: * Biopsy-only of GBM with less than 20% of tumor removed * Prior treatment for GBM (other than surgical resection) * Any known tumor outside of the brain * Recurrent or secondary GBM * Active known or suspected autoimmune disease Other protocol defined inclusion/exclusion criteria could apply